VICAL, INC.

Basic Information

10390 PACIFIC CENTER COURT
SAN DIEGO, CA, 92121

Company Profile

n/a

Additional Details

Field Value
DUNS: 183192855
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: n/a


  1. Herpes Simplex Immunotherapeutic Vaccine

    Amount: $1,999,533.00

    DESCRIPTION (provided by applicant): Herpes simplex viruses infect humans worldwide. In the US, herpes simplex virus type 2 (HSV-2) infects about 17% of adults. Rates are far higher in the developi ...

    STTR Phase II 2008 Department of Health and Human Services
  2. CMV Immunotherapeutic Vaccine

    Amount: $3,137,138.00

    DESCRIPTION (provided by applicant): Vical Inc. of San Diego, Ca. is the largest GMP manufacturer of plasmid DNA for vaccine clinical trials in the world. We have manufactured GMP plasmid DNA vaccines ...

    SBIR Phase II 2005 Department of Health and Human Services
  3. Development of a DNA Vaccine Against Influenza Virus

    Amount: $500,000.00

    DESCRIPTION (provided by applicant): The likely emergence of natural influenza pandemic viruses and the recent expansion of influenza-infected animal carrier reservoirs argue for the rapid development ...

    SBIR Phase I 2005 Department of Health and Human Services
  4. HSV Immunotherapeutic Vaccine

    Amount: $299,616.00

    DESCRIPTION (provided by applicant): The overall goal of this Phase I STTR proposal from the University of Washington (UW) and Vical Incorporated is to advance a multivalent, plasmid DNA (pDNA) immuno ...

    STTR Phase I 2005 Department of Health and Human Services
  5. Development of a Cytomegalovirus DNA Vaccine

    Amount: $263,787.00

    DESCRIPTION (provided by applicant): The specific AIM of this Phase I SBIR proposal from Vical Incorporated is to move forward an immunotherapeutic vaccine for cytomegalovirus (CMV) from preclinical t ...

    SBIR Phase I 2004 Department of Health and Human Services
  6. Prophylactic Anthrax Toxin Vaccine

    Amount: $5,674,947.00

    DESCRIPTION (provided by applicant): Vical Inc. seeks SBIR Phase II funding to develop and produce a licensable prophylactic anthrax vaccine. This project will move on an accelerated but realistic ti ...

    STTR Phase II 2003 Department of Health and Human Services
  7. PROPHYLACTIC ANTHRAX TOXIN VACCINE

    Amount: $462,918.00

    DESCRIPTION (provided by applicant): This STTR grant proposal is for the development of a safe and efficacious Anthrax Toxin Vaccine. The present world-wide threat of the use of anthrax spores as a bi ...

    STTR Phase I 2002 Department of Health and Human Services
  8. N/A

    Amount: $150,769.00

    N/A

    SBIR Phase I 2000 Department of Health and Human Services
  9. DEVELOPMENT OF NUCLEAR TARGETING DNA VACCINE VECTORS

    Amount: $100,000.00

    N/A

    STTR Phase I 1999 Department of Health and Human Services
  10. THERAPEUTIC DNA VACCINES TO TREAT B CELL LYMPHOMA

    Amount: $271,457.00

    Not Available The proposed Phase I program will design active noise and vibration reduction systems for the Advanced Amphibious Assault Vehicle (AAAV) in order to satisfy specific performance-based o ...

    SBIR Phase I 1999 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government